Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo-controlled, 12-week study to evaluate the efficacy and safety of extended release (ER) niacin/laropiprant when added to ongoing lipid-modifying therapy in dyslipidemic patients deemed appropriate for further lipid modification.

Next Previous
X
Search
Trial Profile

A multicenter, randomized, double-blind, placebo-controlled, 12-week study to evaluate the efficacy and safety of extended release (ER) niacin/laropiprant when added to ongoing lipid-modifying therapy in dyslipidemic patients deemed appropriate for further lipid modification.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 09 May 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Niacin/laropiprant (Primary)
  • Indications Dyslipidaemias
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck & Co; Merck Sharp & Dohme

    • Most Recent Events

    • 16 Jul 2008 Status changed from initiated to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 12 Jun 2008 Planned start date for this trial is Sep 2008 as reported by ClinicalTrial.gov
    • 12 Jun 2008 The expected completion date for this trial is extended from Jul 2009 to Nov 2009 as reported by ClinicalTrials.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top